Waldencast PLC

Waldencast PLC(WALD)股票分析

$1.340

-0.020 (-1.47%)收盤時

Loading chart…
High
1.360
Open
1.360
VWAP
1.34
Vol
21.19K
Mkt Cap
478.98M
Low
1.332
Amount
28.48K
EV/EBITDA, TTM
21.75

Waldencast plc is a global multi-brand beauty and wellness platform. It is focused on developing, acquiring, accelerating, and scaling conscious and purpose-driven brands. Its segments include Obagi Medical and Milk Makeup. The Obagi Medical segment sells advanced skincare products backed by science and formulated to minimize signs of skin aging, address dark spots, hyperpigmentation, fine lines and wrinkles, and to protect and enhance skin tone and texture. Its portfolio of medical-grade skincare with consumer-centric, in-office injectable procedures includes Saypha ChIQ, and MagIQ lines of injectable hyaluronic acid gels. The Milk Makeup segment consists of the business of Milk. Its Milk’s business activities include developing, marketing, and selling cosmetics, skincare, and other beauty products. Its Milk Makeup segment offers over 250 products through its United States Website www.MilkMakeup.com and retail partners include Sephora globally and Ulta Beauty in the United States.

AI analysis of Waldencast PLC (WALD)

hold

Waldencast PLC is currently not a strong buy due to its recent financial performance and analyst downgrades, despite some positive catalysts. The stock is trading at $1.34, with a forward P/E of 45.045, suggesting high expectations for future earnings. However, the company reported a Q4 net loss of $33.5 million and has seen a significant decline in its stock price, down 21.64% year-to-date. The main risk is the ongoing strategic review and disappointing sales performance, particularly in the Milk Makeup brand, which could hinder recovery.

估值指標

The current forward P/E ratio for Waldencast PLC (WALD) is 45.05, compared to its 5-year average forward P/E of 20.25.

Forward P/E

Fair
5Y Average P/E
20.25
Current P/E
45.05
高估
141.73
低估
-101.22

Forward EV/EBITDA

Overvalued
5Y Average EV/EBITDA
13.71
Current EV/EBITDA
21.75
高估
20.13
低估
7.29

Forward P/S

Undervalued
5Y Average P/S
1.82
Current P/S
0.55
高估
2.91
低估
0.73

Alphio AI Price Scenarios for WALD

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%WALD

$3.01

情境價格

B

Base

Base · 50%WALD

$2.59

情境價格

B

Bear

Bear · 25%WALD

$2.24

情境價格

事件時間軸

2026-06-15 (ET)

09:30:00

Waldencast Receives FDA Approval for Obagi saypha ChIQ Injectable Hyaluronic Acid Gel

2026-06-02 (ET)

06:50:00

Canaccord Raises Waldencast Price Target to $3

2026-06-01 (ET)

07:40:00

Waldencast Sells Obagi Medical Skincare Business for Up to $460M

2026-03-19 (ET)

08:40:00

Obagi Medical Collaborates with ProMD Health on Hyaluronic Acid Program

2026-03-13 (ET)

07:00:00

Waldencast Reports Q4 Adjusted EBITDA of $6.6M

資訊

WALD FAQ — answered by Alphio AI

Waldencast plc is a global multi-brand beauty and wellness platform. It is focused on developing, acquiring, accelerating, and scaling conscious and purpose-driven brands. Its segments include Obagi Medical and Milk Makeup. The Obagi Medical segment sells advanced skincare products backed by science and formulated to minimize signs of skin aging, address dark spots, hyperpigmentation, fine lines and wrinkles, and to protect and enhance skin tone and texture. Its portfolio of medical-grade skincare with consumer-centric, in-office injectable procedures includes Saypha ChIQ, and MagIQ lines of injectable hyaluronic acid gels. The Milk Makeup segment consists of the business of Milk. Its Milk’s business activities include developing, marketing, and selling cosmetics, skincare, and other beauty products. Its Milk Makeup segment offers over 250 products through its United States Website www.MilkMakeup.com and retail partners include Sephora globally and Ulta Beauty in the United States. It operates in the Consumer Cyclicals sector (PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS industry).

Waldencast PLC is currently not a strong buy due to its recent financial performance and analyst downgrades, despite some positive catalysts. The stock is trading at $1.34, with a forward P/E of 45.045, suggesting high expectations for future earnings. However, the company reported a Q4 net loss of $33.5 million and has seen a significant decline in its stock price, down 21.64% year-to-date. The main risk is the ongoing strategic review and disappointing sales performance, particularly in the Milk Makeup brand, which could hinder recovery.

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

免費開始